AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Original). A recombinant adenoviral vector of serotype 34 which is at least partially deleted in E1 and devoid of E1 activity.

Claim 2 (Original). A population of cells comprising the recombinant adenoviral vector of claim 1.

Claim 3 (Original). A method for producing recombinant, replication-defective adenovirus particles comprising:

(a) transfecting a recombinant adenoviral vector of claim 1 into a population of cells; and

(b) harvesting the resultant recombinant, replication-defective adenovirus.

Claim 4 (Original). Purified recombinant, replication-defective adenovirus particles harvested in accordance with the method of claim 3.

Claim 5 (Original). A composition comprising purified recombinant adenovirus particles in accordance with claim 4.

Claim 6 (Original). A composition in accordance with claim 5 which comprises a physiologically acceptable carrier.

Claim 7 (Original). A recombinant adenoviral vector of serotype 34 which is at least partially deleted in E1 and devoid of E1 activity which comprises heterologous nucleic acid.

Claim 8 (Original). A population of cells comprising the recombinant adenoviral vector of claim 7.

Claim 9 (Original). A method for producing recombinant, replication-defective adenovirus particles comprising:

(a) transfecting a recombinant adenoviral vector of claim 7 into a population of cells; and

(b) harvesting the resultant recombinant, replication-defective adenovirus.

Claim 10 (Original). A recombinant vector in accordance with claim 7 wherein the vector comprises a gene expression cassette comprising:

(a) a nucleic acid encoding a protein;

(b) a heterologous promoter operatively linked to the nucleic acid encoding the protein; and

(c) a transcription termination sequence.

Claim 11 (Original). A recombinant vector in accordance with claim 10 wherein the gene expression cassette is inserted into the E1 region.

Claim 12 (Original). A recombinant vector in accordance with claim 7 wherein the heterologous nucleic acid comprises codons optimized for expression in a human host.

Claim 13 (Original). A recombinant vector in accordance with claim 7 which comprises heterologous nucleic acid in the E1 deletion.

Claim 14 (Original). A recombinant vector in accordance with claim 7 which is at least partially deleted in E3.

Claim 15 (Original). Purified recombinant, replication-defective adenovirus particles harvested in accordance with the method of claim 9.

Claim 16 (Original). A composition comprising purified recombinant adenovirus particles in accordance with claim 9.

Claim 17 (Original). A composition in accordance with claim 16 which comprises a physiologically acceptable carrier.

Claim 18 (Currently amended). A method for effecting the delivery and expression of heterologous nucleic acid comprising administering the composition of claim 16 to

an individual prior or subsequent to administration of the heterologous nucleic acid to the individual with the same or different vector.

Claim 19 (Original). A method in accordance with claim 18 wherein the composition is preceded or followed by administration of heterologous nucleic acid with an adenovirus of a different serotype.

Claim 20 (Original). A composition in accordance with claim 16 wherein the heterologous nucleic acid encodes an HIV antigen.

Claim 21 (Original). A method for generating a cellular-mediated immune response against HIV in an individual comprising administering to the individual a composition of claim 20.

Claims 22-24 (Canceled).

Claim 25 (Original). A recombinant adenoviral vector of serotype 34 which is at least partially deleted in E1 and devoid of E1 activity which comprises an HIV-1 gene.

Claim 26 (Original). A population of cells comprising the recombinant adenoviral vector of claim 25.

Claim 27 (Original). A method for producing recombinant, replication-defective adenovirus particles comprising:

(a) transfecting a recombinant adenoviral vector of claim 25 into a population of cells; and

(b) harvesting the resultant recombinant, replication-defective adenovirus.

Claim 28 (Original). Purified recombinant, replication-defective adenovirus particles harvested in accordance with the method of claim 27.

Claim 29 (Original). A composition comprising purified recombinant adenovirus particles in accordance with claim 28.

Claim 30 (Original). A composition in accordance with claim 29 which comprises a physiologically acceptable carrier.

Claim 31 (Currently amended). A method for effecting the delivery and expression of ~~the~~ an HIV-1 gene comprising administering the composition of claim 30 to an individual prior or subsequent to administration of the HIV-1 gene to the individual with the same or different vector.

Claim 32 (Original). A method in accordance with claim 31 wherein the composition is preceded or followed by administration of the HIV-1 gene with an adenovirus of a different serotype.

Claim 33 (Original). A method for generating a cellular-mediated immune response against HIV in an individual comprising administering to the individual a composition of claim 29.

Claim 34 (Currently amended). A composition in accordance with claim 29 wherein the ~~HIV antigen~~ HIV-1 gene is HIV-1 gag or immunologically relevant modification thereof.

Claim 35 (Currently amended). A composition in accordance with claim 29 wherein the ~~HIV antigen~~ HIV-1 gene is HIV-1 nef or immunologically relevant modification thereof.

Claim 36 (Currently amended). A composition in accordance with claim 29 wherein the ~~HIV antigen~~ HIV-1 gene is HIV-1 pol or immunologically relevant modification thereof.